Calidi Biotherapeutics’ CLD-201 Secures FDA Fast Track for Innovative Glioblastoma Therapy

Calidi Biotherapeutics has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Fast Track designation to its experimental therapy, CLD-201 SuperNova, for the treatment of glioblastoma.…

Continue Reading Calidi Biotherapeutics’ CLD-201 Secures FDA Fast Track for Innovative Glioblastoma Therapy

And the Good News is . . .Cancer Survivors in the United States are Projected to Exceed 22 million people by 2035

Here's a more detailed explanation. The newest American Cancer Society study just released suggests that a diagnosis of cancer is no longer a death sentence. According to a recent U.S.…

Continue Reading And the Good News is . . .Cancer Survivors in the United States are Projected to Exceed 22 million people by 2035

Researchers Find Immunotherapy Drug May Treat Pheochromocytoma

Those diagnosed with paraganglioma-pheochromocytoma, squamous cell carcinoma of the skin (cSCC), adrenocortical carcinoma (ACC), and carcinoma of unknown primary (CUP) may soon have an additional option for treatment. According to…

Continue Reading Researchers Find Immunotherapy Drug May Treat Pheochromocytoma

FDA Grants Orphan Drug Designation to Experimental Acute Lymphoblastic Leukemia Drug

According to a press release from British biopharmaceutical manufacturer Autolus Therapeutics, the American Food and Drug Administration (FDA) has granted the Company's experimental acute lymphoblastic leukemia (ALL) cell-based immunotherapy treatment…

Continue Reading FDA Grants Orphan Drug Designation to Experimental Acute Lymphoblastic Leukemia Drug